3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
2
Gastrointestinal
2
Thoracic
1
Other solid neoplasm
1
Conditions
Stomach Neoplasms
3
Ovarian Neoplasms
3
Peritoneal Neoplasms
2
Mesothelioma, Malignant
2
Mesothelioma
2
Fallopian Tube Neoplasms
2
Colorectal Neoplasms
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Sarcoma
1
Rhabdomyosarcoma
1
Rectal Neoplasms
1
Pseudomyxoma Peritonei
1
Pleural Effusion
1
Pelvic Neoplasms
1
Pancreatic Neoplasms
1
Neoplasm Metastasis
1
Liposarcoma
1
Gastrointestinal Neoplasms
1
Gallbladder Neoplasms
1
Desmoplastic Small Round Cell Tumor
1
Colonic Neoplasms
1
Ascites
1
Appendiceal Neoplasms
1
Interventions
pembrolizumab
8
Nivolumab
3
tislelizumab
2
spartalizumab
2
SS1(dsFv)PE38
2
Ipilimumab
2
fludarabine phosphate
1
fludarabine
1
epacadostat
1
entinostat
1
bosutinib
1
atezolizumab
1
aldesleukin
1
Quality of Life
1
Polymerase Chain Reaction
1
Platinum
1
Pemetrexed
1
Patient Reported Outcome Measures
1
Paclitaxel
1
Molecular Diagnostic Techniques
1
Microarray Analysis
1
Interleukin-2
1
Immunotherapy
1
Immunoenzyme Techniques
1
Hyperthermic Intraperitoneal Chemotherapy
1
Gene Expression Profiling
1
Gemcitabine
1
Flow Cytometry
1
Fentanyl
1
Erlotinib Hydrochloride
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Uterine Cervical Neoplasms
×
Hyperthermic Intraperitoneal Chemotherapy
×
Other solid neoplasm
×
Clear all
NCT02349958
2019-04-16
HIPEC/IPHC
Bay Area Gynecology Oncology
Phase 2
Unknown
200 enrolled